Simultaneous detection of apoptosis and proliferation in colorectal carcinoma by multiparameter flow cytometry allows separation of high and low-turnover tumors with distinct clinical outcome

Cancer

Volumn 97, Issue 10, 2003, Pages 2404-2411

  Rupa, J Dennis ^a   De Bruïne, Adriaan P ^a   Gerbers, Andrea J ^a   Leers, Mathie P G ^b   Nap, Marius ^b   Kessels, Alfons G H ^a   Schutte, Bert ^c   Arends, Jan Willem ^d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d DEVENTER HOSPITAL   (Netherlands)

Author keywords

Apoptosis; Colorectal carcinoma; Flow cytometry; M30; Prognosis; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; PARAFFIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TUMOR CELL; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; CELL DIVISION; CLINICAL TRIAL; COLORECTAL TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NETHERLANDS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SURVIVAL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL DIVISION; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; PARAFFIN EMBEDDING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0037694849     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11366     Document Type: Article

References (33)

1. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000. Cancer incidence, mortality and prevalence worldwide. Available from URL: http://www-dep.iarc.fr/globocan/globocan. html1.
2. Dukes CE. The classification of cancer of the rectum. J Pathol Bacteriol. 1932;35:323-332.
3. Sobin LH, Wittekind Ch. TNM classification of malignant tumours, 5th edition. New York: Wiley-Liss, 1997.
4. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol. 1995;13:2936-2943.
5. Buyse M, Piedbois P. Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol. 2001; 28:20-24.
6. Kerr DJ. A United Kingdom coordinating committee on cancer research study of adjuvant chemotherapy for colorectal cancer: preliminary results. Semin Oncol. 2001;28:31-34.
7. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-532.
8. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
9. Llyas M, Tomlinson IP. Genetic pathways in colorectal cancer. Histopathology. 1996;28:389-399.
10. Arends JW. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol. 2000; 190:412-416.
11. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
12. Reed JC. Mechanisms of apoptosis. Am J Pathol. 2000;157: 1415-1430.
13. Leers MP, Schutte B, Theunissen PH, Ramaekers FC, Nap M. Heat pretreatment increases resolution in DNA flow cytometry of paraffin- embedded tumor tissue. Cytometry. 1999;35: 260-266.
14. Leers MP, Kolgen W, Bjorklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol. 1999;187:567-572.
15. Wiggers T, Jeekel J, Arends JW, et al. No-touch isolation technique in colon cancer: a controlled prospective trial. Br J Surg. 1988;75:409-415.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
17. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;187:567-572.
18. Thunnissen FB, Ambergen AW, Koss M, Travis WD, O'Leary TJ, Ellis IO. Mitotic counting in surgical pathology: sampling bias, heterogeneity and statistical uncertainty. Histopathology. 2001;39:1-8.
19. Key G, Becker MH, Baron B, et al. New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest. 1993;68:629-636.
20. Tang R, Ho YS, You YT, et al. Prognostic evaluation of DNA flow cytometric and histopathologic parameters of colorectal cancer. Cancer. 1995;76:1724-1730.
21. Sun XF, Carstensen JM, Zhang H, Arbman G, Nordenskjold B. Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas. Eur J Cancer. 1996;32A:1963-1967.
22. Zarbo RJ, Nakhleh RE, Brown RD, Kubus JJ, Ma CK, Mackowiak P. Prognostic significance of DNA ploidy and proliferation in 309 colorectal carcinomas as determined by two-color multiparametric DNA flow cytometry. Cancer. 1997;79: 2073-2086.
23. Lanza G, Gafa R, Santini A, et al. Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study. Cancer. 1998;82:49-59.
24. Shankey TV, Rabinovitch PS, Bagwell B, et al. Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry. 1993; 14:472-477.
25. Bagwell CB, Clark GM, Spyratos F, et al. Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens. Cytometry. 2001;46:121-135.
26. Schutte B, Reynders MM, Wiggers T, et al. Retrospective analysis of the prognostic significance of DNA content and proliferative activity in large bowel carcinoma. Cancer Res. 1987;47:5494-5496.
27. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
28. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry. 1998;31:1-9.
29. Jonges LE, Nagelkerke JF, Ensink NG, et al. Caspase-3 activity as a prognostic factor in colorectal carcinoma. Lab Invest. 2001;81:681-688.
30. Evertsson S, Bartik Z, Zhang H, Jansson A, Sun XF. Apoptosis in relation to proliferating cell nuclear antigen and Dukes' stage in colorectal adenocarcinoma. Int J Oncol. 1999;15:53-58.
31. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994;124:619-626.
32. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol. 1999;9:M57-M60.
33. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer prognostic factors consensus conference: Colorectal Working Group. Cancer. 2000;88:1739-1757.